or Connect
HotStockMarket › Forums › HSM Stock Forum › Penny Stocks › CLSN - Celsion Corporation
New Posts  All Forums:Forum Nav:

CLSN - Celsion Corporation

post #1 of 38
Thread Starter 


Celsion Corporation (Celsion) is an oncology drug development company focused on developing drugs for the treatment of various cancer indications. The Company’s product ThermoDox is evaluated in a Phase III clinical trial for primary liver cancer and a Phase II study for recurrent chest wall breast cancer (RCW). ThermoDox is a liposomal encapsulation of doxorubicin, an oncology drug for the treatment of a range of cancers.
post #2 of 38
If this dips a little lower I may get in and hold awhile
post #3 of 38
Bought some today just under $3.00. Hopefully there will be some good news on the 15th the day of their CC.
post #4 of 38
Celsion drug gets 'orphan drug' status in Europe
Celsion's potential liver cancer treatment gets orphan drug designation by European regulators

On Thursday November 11, 2010, 4:57 pm
COLUMBIA, Md. (AP) -- Celsion Corp. said Thursday that European regulators gave the company's potential liver cancer treatment Thermodox orphan drug designation.

Orphan drug status is given to drugs aimed at rare conditions or diseases for which there are few if any treatments on the market. Incentives in Europe include 10 years of market exclusivity if the drug is approved, along with reduced fees and assistance from the European Medicines Agency during the development phase.

Thermodox is currently in late-stage development and has already received orphan drug designation from the Food and Drug Administration. The U.S. incentives include seven years of market exclusivity following FDA approval, assistance in clinical trial design, a reduction in user fees, and tax credits.

Shares of Celsion rose 16 cents, or 5.5 percent, to close at $3.06. The stock has traded between $2.71 and $5.63 over the last 52 weeks.

http://finance.yahoo.com/news/Celsio....html?x=0&.v=1
post #5 of 38



Looks like this one finally found a bottom and is coming back. I think they did some dilluiting at the start of December
post #6 of 38
Very nice close!!!!!!!!!!!!
post #7 of 38
up another 6% today
post #8 of 38



This is the perfect time to load up the truck before the BIG News coming .

Phase 3 interim data for their potential blockbuster Thermodox + NDA submission + New Partnership  <<  all this News coming very soon .

See you guys in the Double Digits before year end .GLTA


Celsion (CLSN)

Market Cap : 38 M
Price : 2.90

Shares Out: 14 M  // 8 M shares owned by Insiders/Institutions


.........
Some Slides from Cowen Presentationmag-glass_10x10.gif (March 2011)

Phase 3 interim analysis this Q
http://www.wsw.com/webcast/cowen3/clsn/2__Slide15.JPG

Rolling NDA + Priority review in 2011
http://www.wsw.com/webcast/cowen3/clsn/2__Slide6.JPG

Multibillion Dollar Potential for Thermodox
http://www.wsw.com/webcast/cowen3/clsn/2__Slide21.JPG

Near Term Milestones
http://www.wsw.com/webcast/cowen3/clsn/2__Slide24.JPG

Mega Pipeline
http://www.wsw.com/webcast/cowen3/clsn/2__Slide5.JPG

Liver cancer expected to be the Number 1 cancer by 2020
http://www.wsw.com/webcast/cowen3/clsn/2__Slide9.JPG

Strong Patent till 2018
http://www.wsw.com/webcast/cowen3/clsn/2__Slide4.JPG

Commercialization strategy
http://www.wsw.com/webcast/cowen3/clsn/2__Slide22.JPG

Financialmag-glass_10x10.gif summary
http://www.wsw.com/webcast/cowen3/clsn/2__Slide23.JPG

post #9 of 38

But they are pretty much broke and losing millions every month.  But that's why the market cap is pretty low considering.

 

 

post #10 of 38

UPDATE ...


Thermodox (liver cancer) Phase 3 interim data + NDA submission + New Partnership >>> all this News coming very soon .Market cap of 43 million is RIDICULOUS .

Celsion has the potential to be the next Dendreon .The Runup has just begun..GL


Celsion (CLSN)

Market Cap : 43 M
Cash: 10-11 M$
Price : 3.13 $

Shares Out: 15 M


Product Pipeline
http://www.celsion.com/pipeline.cfm

Gekkowire Article ...A MUST READ
http://www.gekkowire.com/?p=7671

Insider Activity
http://www.secform4.com/insider-trading/749647.htm

.........
Some Slides from Cowen Presentation (March 2011)

Phase 3 interim analysis this Q
http://www.wsw.com/webcast/cowen3/clsn/2__Slide15.JPG

Rolling NDA + Priority review in 2011
http://www.wsw.com/webcast/cowen3/clsn/2__Slide6.JPG

Multibillion Dollar Potential for Thermodox
http://www.wsw.com/webcast/cowen3/clsn/2__Slide21.JPG

Near Term Milestones
http://www.wsw.com/webcast/cowen3/clsn/2__Slide24.JPG

Mega Pipeline
http://www.wsw.com/webcast/cowen3/clsn/2__Slide5.JPG

Liver cancer expected to be the Number 1 cancer by 2020
http://www.wsw.com/webcast/cowen3/clsn/2__Slide9.JPG

Strong Patent till 2018
http://www.wsw.com/webcast/cowen3/clsn/2__Slide4.JPG

Commercialization strategy
http://www.wsw.com/webcast/cowen3/clsn/2__Slide22.JPG

Financial summary
http://www.wsw.com/webcast/cowen3/clsn/2__Slide23.JPG

post #11 of 38

Anyone holding this? should have some ph3 data coming soon..

post #12 of 38

06/08/11 -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that after reviewing safety data from the Company's recently completed Phase I portion of the DIGNITY Phase I/II study of ThermoDox® and hyperthermia in recurrent chest wall (RCW# breast cancer #the DIGNITY Study#, an independent Drug Safety Monitoring Board #DSMB# has recommended advancing from Phase I to Phase II at 50 mg/m2 of ThermoDox®.

 

The DIGNITY Study is a multicenter, single-arm, open-label, potentially registrational trial enrolling up to 109 patients with RCW breast cancer. The study is designed to evaluate the potential for ThermoDox® in combination with hyperthermia to provide local control of superficial breast cancer recurrence. The primary endpoint is durable complete local response. The DIGNITY Study builds upon promising data from a Phase I dose escalation study conducted at the Duke University Medical Center, in which patients #n=16) demonstrated evidence of clinical activity, either stable disease, partial response or complete response. Toxicities are consistent with doxorubicin, the active agent in ThermoDox® and a widely used chemotherapeutic with a well established safety profile 

 

http://wp.me/pziP4-5m

post #13 of 38

This one has been moving up nicely the past couple of days

 

post #14 of 38

This motor scooter has been on fire.  I am predicting over $3 this week

 

big.chart?nosettings=1&symb=clsn&uf=0&type=4&size=3&sid=2233249&style=330&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=8&rand=1660036673&compidx=aaaaa%3a0&ma=0&maval=9&lf=1&lf2=0&lf3=0&height=510&width=720&mocktick=1

post #15 of 38

Just hit $3.  Sooner than I thought.  How long can this keep going up?

post #16 of 38

just got turned on to this one here recently... the insider trading alone should tell you something. could be a nice strong buy... looking to enter

post #17 of 38

Strong move recently.  Insiders still buying and data should be released within a month or so. Anyone still in?

post #18 of 38
I am tied up very heavy in CTIX, but if i wasnt this would be my next big move. Heading to 15 in january when trial results hit
post #19 of 38

Looks like it may continue yesterdays run

post #20 of 38
Ouch. 7:38AM Celsion trading down 84% on disappointing Phase III data on ThermoDox in Primary Liver Cancer; Study did not provide sufficient evidence of clinical effectiveness (CLSN) 8.02 : I think I'm in for a rebound play..
New Posts  All Forums:Forum Nav:
  Return Home
  Back to Forum: Penny Stocks
HotStockMarket › Forums › HSM Stock Forum › Penny Stocks › CLSN - Celsion Corporation